Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance
Mjriam Capula, Macarena Perán, Geng Xu, et al.
Drug Resistance Updates (2022) Vol. 64, pp. 100864-100864
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance
Xu Guo, Congying Gao, Dong‐Hua Yang, et al.
Drug Resistance Updates (2023) Vol. 67, pp. 100937-100937
Closed Access | Times Cited: 87
Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities
Qin Qin, Rong Yu, John Eriksson, et al.
Cancer Letters (2024) Vol. 591, pp. 216859-216859
Open Access | Times Cited: 13
Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer
Wei Zhang, Yibao Fan, Jinze Zhang, et al.
Drug Resistance Updates (2023) Vol. 71, pp. 101005-101005
Open Access | Times Cited: 27
Emerging mechanisms and promising approaches in pancreatic cancer metabolism
Hao Wu, Mengdi Fu, Mengwei Wu, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 8
Open Access | Times Cited: 6
CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy
Zhide Liu, Yin-Hao Shi, Qiong‐Cong Xu, et al.
Cancer Letters (2024) Vol. 585, pp. 216640-216640
Open Access | Times Cited: 5
Conquering chemoresistance in pancreatic cancer: Exploring novel drug therapies and delivery approaches amidst desmoplasia and hypoxia
Pavan Kumar Chintamaneni, Sai Kiran S. S. Pindiprolu, Swati Swagatika Swain, et al.
Cancer Letters (2024) Vol. 588, pp. 216782-216782
Open Access | Times Cited: 5
CD63+ cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to breast cancer cells by exosomal miR-20
Jiahui Sun, Ruoxin Du, Xiaoju Li, et al.
Cancer Letters (2024) Vol. 588, pp. 216747-216747
Open Access | Times Cited: 4
Extracellular vesicles from Fusobacterium nucleatum : roles in the malignant phenotypes of gastric cancer
Xiangkun Meng, Gang Ma, Xu Zhang, et al.
Cell Cycle (2024) Vol. 23, Iss. 3, pp. 294-307
Closed Access | Times Cited: 4
Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
Inês Mendes, Nuno Vale
Biomedicines (2024) Vol. 12, Iss. 1, pp. 227-227
Open Access | Times Cited: 3
Dynamic Immunoediting by Macrophages in Homologous Recombination Deficiency-Stratified Pancreatic Ductal Adenocarcinoma
Weifeng Hong, Feng Zhang, Nan Wang, et al.
Drug Resistance Updates (2024) Vol. 76, pp. 101115-101115
Closed Access | Times Cited: 3
The emerging tumor microbe microenvironment: From delineation to multidisciplinary approach-based interventions
Yu Fu, Jia Li, Wenyun Cai, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 4, pp. 1560-1591
Open Access | Times Cited: 10
Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic challenges
Zhichen Jiang, Xiaohao Zheng, Min Li, et al.
Frontiers of Medicine (2023) Vol. 17, Iss. 6, pp. 1135-1169
Closed Access | Times Cited: 8
Exploring the therapeutic potential of a novel series of imidazothiadiazoles targeting focal adhesion kinase (FAK) for pancreatic cancer treatment: Synthesis, mechanistic Insights and promising antitumor and safety profile
Daniela Carbone, Camilla Pecoraro, Fabio Scianò, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Exploring the therapeutic potential of a novel series of imidazothiadiazoles targeting focal adhesion kinase (FAK) for pancreatic cancer treatment: synthesis, mechanistic insights and promising antitumor and safety profile
Camilla Pecoraro, Daniela Carbone, Fabio Scianò, et al.
Journal of drug targeting (2024) Vol. 32, Iss. 10, pp. 1278-1294
Open Access | Times Cited: 2
6-Phosphogluconate dehydrogenase promotes glycolysis and fatty acid synthesis by inhibiting the AMPK pathway in lung adenocarcinoma cells
Jun Wu, Yong Chen, Hui Zou, et al.
Cancer Letters (2024) Vol. 601, pp. 217177-217177
Open Access | Times Cited: 2
Moracin D suppresses cell growth and induces apoptosis via targeting the XIAP/PARP1 axis in pancreatic cancer
Xi Zhong, Xiaoxue Ke, Yang He, et al.
Phytomedicine (2024) Vol. 128, pp. 155527-155527
Closed Access | Times Cited: 1
The correlation between gut and intra-tumor microbiota and PDAC: Etiology, diagnostics and therapeutics
Jiwei Qian, Xin Zhang, Butian Wei, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 5, pp. 188943-188943
Closed Access | Times Cited: 5
Bacteria-driven cancer therapy: Exploring advancements and challenges
Syed Riaz Ud Din, Sumbul Saeed, Shahid Ullah Khan, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 191, pp. 104141-104141
Open Access | Times Cited: 5
Efficacy of HMJ-38, a new quinazolinone analogue, against the gemcitabine-resistant MIA-PaCa-2 pancreatic cancer cells
Mann‐Jen Hour, Fuu Jen Tsai, I‐Lu Lai, et al.
Biomedicine (2023) Vol. 13, Iss. 4, pp. 20-31
Open Access | Times Cited: 5
The role of histone H1.2 in pancreatic cancer metastasis and chemoresistance
Jianyou Gu, Junfeng Zhang, Renpei Xia, et al.
Drug Resistance Updates (2023) Vol. 73, pp. 101027-101027
Closed Access | Times Cited: 4
Exosomal circular RNAs: A key player in cancer drug resistance
Abduladheem Turki Jalil, Mohanad Ali Abdulhadi, Lubna R. Al-Ameer, et al.
Gene Reports (2023) Vol. 33, pp. 101835-101835
Closed Access | Times Cited: 2
Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor tivantinib in pancreatic cancer
Mahrou Vahabi, Geng Xu, Amir Avan, et al.
Nucleosides Nucleotides & Nucleic Acids (2024) Vol. 43, Iss. 8, pp. 837-850
Closed Access
Anticancer sensitivity and biological aspect of 5-fluorouracil-resistant human colorectal cancer HCT116 cells in three-dimensional culture under high- and low-glucose conditions
Chinatsu Kurasaka, Nana Nishizawa, Yoko Ogino, et al.
Nucleosides Nucleotides & Nucleic Acids (2024), pp. 1-11
Closed Access
Ubiquitin ligase TRIM15 promotes the progression of pancreatic cancer via the upregulation of the IGF2BP2-TLR4 axis
Hongkun Cai, Jingyuan Zhao, Qiyue Zhang, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 5, pp. 167183-167183
Closed Access
Natural products as inhibitors against pancreatic cancer cell proliferation and invasion: possible mechanisms
Xiang Li, Yang Xu, Wei Guo, et al.
American Journal of Cancer Research (2024) Vol. 14, Iss. 6, pp. 2695-2713
Closed Access
Page 1 - Next Page

Scroll to top